Cryoport (CYRX) Competitors $7.86 +0.12 (+1.55%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CYRX vs. RCUS, KNSA, IMCR, OCUL, MESO, TVTX, NTLA, PRAX, ARVN, and DAWNShould you be buying Cryoport stock or one of its competitors? The main competitors of Cryoport include Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), Praxis Precision Medicines (PRAX), Arvinas (ARVN), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Cryoport vs. Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Travere Therapeutics Intellia Therapeutics Praxis Precision Medicines Arvinas Day One Biopharmaceuticals Arcus Biosciences (NYSE:RCUS) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Does the media refer more to RCUS or CYRX? In the previous week, Arcus Biosciences had 2 more articles in the media than Cryoport. MarketBeat recorded 5 mentions for Arcus Biosciences and 3 mentions for Cryoport. Cryoport's average media sentiment score of 0.97 beat Arcus Biosciences' score of 0.78 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer RCUS or CYRX? Cryoport received 48 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 65.54% of users gave Arcus Biosciences an outperform vote while only 65.05% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformArcus BiosciencesOutperform Votes19465.54% Underperform Votes10234.46% CryoportOutperform Votes24265.05% Underperform Votes13034.95% Which has more volatility and risk, RCUS or CYRX? Arcus Biosciences has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Which has stronger valuation & earnings, RCUS or CYRX? Cryoport has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Cryoport, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$263M5.39-$307M-$3.15-4.92Cryoport$226.11M1.72-$99.59M-$3.38-2.33 Do insiders and institutionals believe in RCUS or CYRX? 92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 92.9% of Cryoport shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by insiders. Comparatively, 10.1% of Cryoport shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is RCUS or CYRX more profitable? Cryoport has a net margin of -70.08% compared to Arcus Biosciences' net margin of -102.66%. Cryoport's return on equity of -13.35% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-102.66% -45.59% -22.38% Cryoport -70.08%-13.35%-6.43% Do analysts prefer RCUS or CYRX? Arcus Biosciences presently has a consensus price target of $34.00, suggesting a potential upside of 119.35%. Cryoport has a consensus price target of $12.29, suggesting a potential upside of 56.31%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Cryoport 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryArcus Biosciences beats Cryoport on 10 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Cryoport News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoportPharmaceutical IndustryTransportation SectorNASDAQ ExchangeMarket Cap$388.53M$6.58B$303.23B$9.07BDividend YieldN/A2.99%4.46%4.23%P/E Ratio-2.3310.4617.8117.17Price / Sales1.72195.7955.77116.95Price / Cash21.0657.1613.0337.86Price / Book0.835.092.114.78Net Income-$99.59M$151.83M$577.06M$225.60M7 Day Performance2.21%-2.13%-2.46%-1.23%1 Month Performance19.54%-3.10%-3.27%3.36%1 Year Performance-51.57%11.54%-0.71%16.60% Cryoport Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoport3.0208 of 5 stars$7.86+1.6%$12.29+56.3%-49.8%$388.53M$226.11M-2.331,170Analyst ForecastGap DownRCUSArcus Biosciences2.6476 of 5 stars$16.22+0.9%$34.00+109.6%-9.3%$1.48B$117M-5.11500News CoverageKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.36+0.8%$36.60+79.8%+15.4%$1.47B$384.10M-147.36220Positive NewsIMCRImmunocore2.4974 of 5 stars$29.15+0.8%$65.64+125.2%-51.4%$1.46B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.6461 of 5 stars$9.03+3.9%$16.71+85.1%+116.8%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.043 of 5 stars$12.16+3.4%$11.50-5.4%+590.1%$1.39B$5.90M0.0080Analyst ForecastOptions VolumeNews CoveragePositive NewsTVTXTravere Therapeutics2.7698 of 5 stars$17.65+1.9%$22.62+28.1%+106.0%$1.38B$145.24M-3.81460Positive NewsNTLAIntellia Therapeutics4.132 of 5 stars$13.50+4.7%$54.94+306.9%-58.9%$1.37B$36.28M-2.37600PRAXPraxis Precision Medicines2.4033 of 5 stars$71.98+2.6%$146.33+103.3%+323.0%$1.34B$2.45M-7.06110High Trading VolumeARVNArvinas2.031 of 5 stars$19.35-0.8%$63.50+228.2%-49.3%$1.33B$78.50M-4.18445DAWNDay One Biopharmaceuticals1.6211 of 5 stars$12.74-0.1%$35.71+180.3%-7.7%$1.28B$101.95M-12.3860 Related Companies and Tools Related Companies Arcus Biosciences Competitors Kiniksa Pharmaceuticals Competitors Immunocore Competitors Ocular Therapeutix Competitors Mesoblast Competitors Travere Therapeutics Competitors Intellia Therapeutics Competitors Praxis Precision Medicines Competitors Arvinas Competitors Day One Biopharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cryoport, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cryoport With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYRX Stock Alerts